NASDAQ: ABUS · Life Sciences · 4 alerts · CIK 1447028
Share price
$4.04Close, Nov 16
Market cap
$619M
Shares outstanding
153.29MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Arbutus Biopharma Corp filings on SEC EDGAR ↗
Arbutus Biopharma Corporation has posted an updated corporate presentation for Q4 2026 to its website and filed it with the SEC. The presentation outlines the company's strategic focus on developing a functional cure for chronic hepatitis B virus (HBV), including the clinical development of its lead candidate imdusiran. The filing serves as a routine update for investors regarding the company's pipeline, clinical trial designs, and future prospects.
Arbutus Biopharma reported a significant net income of $223.7 million for the nine months ended September 30, 2026, primarily driven by a $178.4 million settlement payment from Moderna and $67.3 million in dividend income. This represents a major turnaround from a net loss of $29.7 million in the prior year period, significantly strengthening the company's cash position to $264.2 million.
Arbutus Biopharma reported Q3 2026 financial results, highlighting a strong cash position of $337.5 million following a $178.4 million settlement payment from Moderna. The company also announced expanded patent infringement litigation against Pfizer and BioNTech in Japan and Canada regarding its LNP technology.
Term
Q3 2026
“This has been a busy and productive quarter for the Arbutus team. I would like to congratulate our finance team, which successfully returned a substantial portion of Moderna’s first patent infringement payment to shareholders, and our R&D team, for achieving the lift of the 2023 U.S. FDA clinical hold on our oral PD-L1 inhibitor, AB-101, following a successful Phase 1 trial abroad.”
Arbutus Biopharma announced that the FDA has lifted the clinical hold on the Investigational New Drug (IND) application for AB-101, its oral PD-L1 inhibitor. The company is now authorized to resume clinical development of the candidate in the United States and is evaluating next steps for its continued development. AB-101 is being developed as a potential treatment for chronic hepatitis B virus (cHBV) infection.